Tarilian Laser Technologies achieves greatest technological advance in blood pressure measurement for 130 years

New optical sensor makes current blood pressure measurement devices obsolete

7 December 2011. Welwyn Garden City, UK. – Tarilian Laser Technologies (TLT) has invented a completely novel method of measuring blood pressure based on an optical sensor, reports Medical Technology Business Europe. The sensor outperforms the current “gold standard” for measuring blood pressure and effectively makes the older technology obsolete. The accuracy, breadth of data recorded, size and ease of use of the sensor are likely to have a profound effect on blood pressure measurement in the clinical setting, medical research and also home healthcare.

TLT’s first product is a highly innovative consumer blood pressure device that is cuff-based and has unique features including superior accuracy and ease of use compared to current devices. Also, unlike other devices it does not need calibration to ensure accuracy of readings. The company is now completing the manufacturing scale-up and translation programme and expects to enter significant sales revenue by 2012. It has already secured advanced sales interest in this device, with first-year volumes expected to reach about 1 million units.

TLT’s next-generation Sapphire sensor system allows direct measurement of blood pressure without a cuff within seconds. A further advantage is that the sensor doesn’t just measure blood pressure, it generates a continuous beat-to-beat blood pressure measurement and other ‘haemodynamic’ data, which in combination enable it to give a more complete vascular assessment than any other blood pressure device. This will give clinicians a much improved toolset for monitoring, diagnosing and treating patients suffering from a wide range of diseases.

These abilities alone make it a world-beating technology, but what makes the sensor even more groundbreaking is its ability to measure blood pressure on virtually any part of the body without exerting pressure and with no energy entering the body. This creates additional unique applications:

  • blood pressure measurement of the eye without putting pressure on the eye;
  • foetal heart monitor;
  • health and blood pressure of the arteries in the leg;
  • health and blood pressure of the neck arteries (the carotid); and
  • highly accurate miniature sports biometric devices.

This miniature sensor will also make it possible to put blood pressure sensing technology into a completely new range of devices, such as a bracelet, plaster, pen, computer mice, mobile phones and clothing, so that the measurement of blood pressure could become completely innocuous and ubiquitous, while still achieving a high level of accuracy. With the growing use of healthcare in the home — as emphasised by David Cameron’s announcement of the 3 Million Lives Campaign to use telecare to monitor patients’ health in the home — the sensor provides a much simpler and accurate way to take the blood pressure of patients automatically and transmit the data to a telecare device.

Dr Sandeep Shah, CEO of TLT, said, “This an exciting time for us. The TLT company was founded and developed in Hertfordshire, UK and within a short period of time, we have broken the barrier on sensor capabilities with our novel optical technology. The TLT sensor, because of its power, simply makes other technologies in medical biometrics obsolete, so we see the potential to have our sensor in every blood pressure device — which is a potential worldwide market expanding to a projected 100 million devices a year — projecting TLT into a billion plus dollar company within a short period of time.”

“The technology is very scaleable and affordable; and indeed can compete extremely well with current costs within the BPM sector, and yet it offers unique and powerful advantages over all other technologies. These features simply do not exist with any other technology and this makes TLT a disruptive technology that has both redefined the state of the art of blood pressure monitoring and one that has created a paradigm shift in cardiovascular medicine. It has even been suggested that the ability of the TLT sensor to collect such a rich set of data on the cardiovascular system has opened up a whole new area of physiology.

Furthermore we have created a unique proprietary production process of this optical sensor to manufacture large volumes, making us ready to capture this market with ease.”

Dr Art Tucker, Principal Clinical Scientist and Vascular Researcher at St Bartholomew’s Hospital, London, said, “The TLT sensor is a highly novel promising new technology that will have a large and positive impact in this field. It is an exciting and powerful new development in vascular science and has created a new state of the art in blood pressure measurement. It will no doubt be of great value both in hospitals and primary care as well as at home for the consumer, and offers a new paradigm in vascular biometrics.”

Dr David Jefferys, ex Chief Executive and Director of the UK Medical Devices Agency, current President of The Organisation for Professionals in Regulatory Affairs (TOPRA), said, “Blood pressure is a critical biometric measurement in medicine and has ubiquitous utility in all areas of medicine and also in research, including pharmaceutical trials. There has been significant controversy and debate about the current BPM technologies — ausculatory, oscillometry and tonometry, especially. A lot of this debate has centred around the inaccuracies and the poor reliability of these systems, which has led to a series of regulatory concerns and investigations by the MHRA, US FDA and also AAMI.”

“These concerns are of serious nature,” Dr Jefferys continued, “not just relating to causative morbidity but also mortality. Indeed, of particular note are the concerns of poor performance of these systems in sub-populations eg the elderly, children and also in pregnancy. A series of recent papers has highlighted technical performance issues with these older systems and also the limitations of their accuracy and reliability. Hence, there is a clear need for a better and more accurate, more robust, versatile technology to be made available within this critical field of medicine — not just from the view of experts but also from a general patient and consumer perspective.”

“Simply put,” said Dr Jefferys, “the TLT Technology offers a significant competitive advantage to all others that are in the market. Furthermore, TLT’s Sapphire cuffless sensor promises to deliver a sophisticated and elegant solution to future demands within this sector. The TLT Sapphire sensor development has created a pioneering platform from which further technological advances in haemodynamic profiling may be realised and thus improve the management of an array of medical conditions.”

Dr Shah concluded: “I often reflect on what I would like to achieve in my career in medicine and medical technology development, and to have created the world’s first unique optical sensor that accurately generates a carotid and eye BP makes me feel very satisfied and proud. The benefit to patients and also to the healthy to prevent disease is huge, and of course the associated commercial opportunity is also huge — into the billions of dollars! I believe that when we scale up our future developments at TLT, we will deliver an innovation explosion in further applications of our technology. And what’s more, it makes me proud that we intend to create up 19 new jobs in the first year of production and rising to over 60 in year three.”

– ends –

Image captions

(images are at end of document or attached and in the full article – see link below)
TLT sensor image 1 – The actual core TLT optoelectronic sensor base. This is all that is required to make the BP measurement itself. No cuff is needed.
TLT sensor image 2 – Schematic of the overall TLT core sensor
TLT sensor image 3 – Cut-through TLT sensor within outside casing

Information for editors

The full article is published at:http://www.mtbeurope.info/content/ft1112001.htm  (no access restrictions).

Please send a link to any story published online, and if published in print, a PDF or paper copy (sent to address below).

For further press information, please contact
Harry Wood, Medical Technology Business Europe
Tel : +44 (0)1252 691 590
harry.wood [at] mtbeurope.info

About Tarilian Laser Technologies

Tarilian Laser Technologies (TLT) was established in 2006 by Dr Sandeep Shah, CEO, and Nita Shah, Programme Director, to further develop optical technology that they had discovered could measure blood pressure in a unique way. Following completion of the research programme the company filed a series of patents and set up an international R&D team to progress with the development of the sensor technology. TLT has already successfully completed its international FDA and MHRA pivotal regulatory clinical trial, working with global experts in clinical medicine and clinical trials, including from Barts Hospital, London and the William Harvey Institute, London. TLT is now completing the development and entering the manufacturing translation and scale-up programme for its highly innovative consumer blood pressure device that is a stand-alone cuff-less device and has unique features including superior accuracy and ease of use. TLT is expecting first year sales revenue of its TLT Sapphire innovative device to reach over 1 million units. Tarilian Laser Technologies is headquartered in Welwyn Garden City, Hertfordshire, UK.


Dr Sandeep Shah CEO, Tarilian Laser Technologies.
Tel: +44 (0) 1707 356 112
Email: sandeep [at] tarilian-group.com
Website: www.tarilian-lasertechnologies.com

Problems with current methods of blood pressure measurement

The most common method of blood pressure measurement dates back to the 19th century. Although the method of indirect measurement of blood pressure was developed earlier, the first practical device, Von Basch’s sphygmomanometer, was invented in 1881. Since then there have been gradual improvements in the technique, called oscillometry, but the basic principal — of compressing the arm and measuring the pressure that impedes pulsation of the blood (systolic pressure) and taking a second measurement at the point the pulsation returns after releasing the compression (diastolic pressure) — has not changed. Oscillometry was not commercialised until the 1980s and has poor patent protection. It is unreliable, inaccurate and difficult to use. Many devices on the market are unvalidated and have unacceptable levels of inaccuracy.

Other technologies appeared in the late 1990s and early 2000s but these also suffer from inaccuracies. Tonometry, for example, is very sensitive to the positioning of the sensor (and hence is fiddly and cumbersome to use) suffers from great variability in readings and uses a ‘surrogate’ measurement to derive blood pressure. It also requires frequent calibration with oscillometric systems to ensure accuracy. In addition, there are difficulties in measuring blood pressure in certain patient groups: the elderly, patients with arrhythmias, obese patients, children and pregnant women. Oscillometry is also plagued by problems and is thus questionable in terms of reliability and accuracy.

Hypertension experts have long reported on the shortcomings of current systems of blood pressure measurement — there is a large amount of evidence published in medical journals — and recently regulatory bodies have also become increasingly concerned about the performance of current devices.

The importance of blood pressure measurement

Blood pressure is one of the most fundamental measurements taken in healthcare. It is the most common after pulse and temperature, but the most informative to healthcare decision making. Raised blood pressure is the most significant cause of death and disability worldwide (Lopez et al, 2006) and over 2 billion people suffer from high blood pressure.

The monitoring of blood pressure has strong applications in many clinical fields including in stroke prevention, obstetrics, neurology, vascular medicine and diabetes.

For further press information, please contact:
Harry Wood
Tel : +44 (0)1252 691 590
harry.wood [at] mtbeurope.info
Medical Technology Business Europe, 29 Pinewood Park, Farnborough, Hampshire, UK
Web: www.mtbeurope.info
Twitter: www.twitter.com/mtbeurope

Images (right click to save)

TLT sensor image 1 – The actual core TLT optoelectronic sensor base. This is all that is required to make the blood pressure measurement itself. No cuff is needed. (full size 992x331px)

TLT sensor image 1 - The actual core TLT optoelectronic sensor base.
This is all that is required to make the BP measurement itself. No cuff is needed.


TLT sensor image 2 – Schematic of the overall TLT core sensor

TLT sensor image 2 - Schematic of the overall TLT core sensor


TLT sensor image 3 – Cut-through TLT sensor within outside casing

TLT sensor image 3 - Cut-through TLT sensor within outside casing


The TLT cuff-based blood pressure measurement device that uses the same sensor (full size: 1092×692)

Related Posts